Nepali Reaches Summit of Everest for Record 30th Time 

Veteran Sherpa guide Kami Rita returning after scaling Mount Everest for the 28th time arrives at the airport in Kathmandu, Nepal, May 25, 2023. (AP)
Veteran Sherpa guide Kami Rita returning after scaling Mount Everest for the 28th time arrives at the airport in Kathmandu, Nepal, May 25, 2023. (AP)
TT

Nepali Reaches Summit of Everest for Record 30th Time 

Veteran Sherpa guide Kami Rita returning after scaling Mount Everest for the 28th time arrives at the airport in Kathmandu, Nepal, May 25, 2023. (AP)
Veteran Sherpa guide Kami Rita returning after scaling Mount Everest for the 28th time arrives at the airport in Kathmandu, Nepal, May 25, 2023. (AP)

Nepali climber Kami Rita Sherpa broke his own record Wednesday as the person to have scaled Mount Everest the most times, achieving the milestone 30th ascent of the world's highest peak.

The 54-year-old, known as "Everest Man", reached the summit for the 29th time earlier this month, before climbing to the top again.

"Kami Rita reached the summit this morning. Now he has made a new record with 30 summits of Everest," Mingma Sherpa of Seven Summit Treks, his expedition organizer, told AFP.

A guide for more than two decades, Sherpa first stood on the 8,849-meter (29,000-foot) peak in 1994 when working for a commercial expedition.

Since then he has climbed Everest almost every year, guiding clients.

"I am glad for the record, but records are eventually broken," he told AFP after his 29th climb on May 12.

"I am more happy that my climbs help Nepal be recognized in the world."

Last year, Sherpa climbed Everest twice to reclaim his record after another guide, Pasang Dawa Sherpa, equaled his number of ascents.

Kami Rita Sherpa previously said that he has been "just working" and did not plan on setting records.

He has also conquered other 8,000-meter peaks including the world's second-highest mountain, K2 in Pakistan.

- Romanian climber dies -

His success on reaching the top came as the season's death toll climbed to five.

A Romanian climber died during a bid to scale Lhotse, the fourth-highest mountain, his expedition organizer said.

"He was found dead in his tent on Camp Three on Monday morning by his guide," said Mohan Lamsal of Makalu Adventure, naming the climber as Gabriel Viorel Tabara.

Everest and Lhotse share the same route until diverting at 7,200 meters.

"We are making efforts to bring his body down," he said.

Earlier this week, two Mongolian climbers went missing and were later found dead after summiting Everest.

Two more climbers, one French and one Nepali, have died this season on Makalu, the world's fifth-highest peak.

Nepal has issued more than 900 permits for its mountains this year, including 419 for Everest, earning more than $5 million in royalties.

Around 500 climbers and their guides have already reached the summit of Everest after a rope-fixing team reached the peak last month.

This year, China also reopened the Tibetan route to foreigners for the first time since closing it in 2020 because of the pandemic.

Nepal is home to eight of the world's 10 highest peaks and welcomes hundreds of adventurers each spring, when temperatures are warm and winds typically calm.

Last year more than 600 climbers made it to the summit of Everest, but it was also the deadliest season on the mountain, with 18 fatalities.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”